Sigachi Industries Shares Rally 10% On Submission of CEP Filing For Propafenone Hydrochloride

Due to its positive path, Sigachi Industries' shares attracted a lot of market attention on Friday. The stock gained 10% from its previous close of Rs 51.13 after opening on the NSE at Rs 51 and rising to an intraday high of Rs 56.20. The stock was trading 6.73% higher at Rs 54.57 a share at 1:59 p.m. IST. Trimax Biosciences Pvt Ltd, a Sigachi Group Company, got a communication from the European Directorate for the Quality of Medicines & Health Care (EDQM) on its most recent CEP Filing submission of "Propafenone Hydrochloride," which prompted this rally, according to Sigachi Industries Limited.

The company will be allowed to export this product in Europe and other CEP-accepting nations after it has obtained the Certificate of Suitability for this API. This is a big step in guaranteeing the highest standards of product quality and safety as well as European regulatory norms. Additionally, Sigachi's revenue streams will be deliberately diversified to generate more value for every stakeholder. With a current worldwide market value of USD 1.2 billion, propafenone hydrochloride is a highly sought-after API that is frequently used to treat cardiac arrhythmias.

The market is anticipated to develop at a compound annual growth rate (CAGR) of 7%, reaching USD 2.1 billion by 2032. The rising incidence of cardiovascular illnesses, the expanding use of generic drugs, and the rising cost of healthcare worldwide are the main causes of this development.

According to Sigachi Industries, it is dedicated to providing excellence by meeting the demands of highly regulated markets, such as the EU, while maintaining compliance and the highest quality standards through modern production capabilities.

Commenting on this development, Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited said "The submission of our first CEP filing is a testament to Trimax Biosciences' commitment to quality, compliance, and innovation in the API domain. This achievement not only strengthens our position in the pharmaceutical supply chain but also aligns with our vision of providing reliable and sustainable pharmaceutical solutions on a global scale."

When compared to Q2FY24, when net revenues were Rs 80.26 crore, Sigachi Industries' Q2FY25 net revenues were Rs 123.66 crore. In addition, the company's net profit for the quarter increased significantly to Rs 21.72 crore from Rs 8.37 crore during the same period the previous year. While net profit rose from Rs 18.51 crore to Rs 31.01 crore in the first two-quarters of FY24, Sigachi's net revenue for the first two-quarters of FY25 was Rs 205.47 crore, up from Rs 159.73 crore in the previous reporting session.

Trimax Bio Sciences Private Limited, a subsidiary of Sigachi Industries Limited, was established on May 11, 2010, and focuses on the creation and production of sophisticated intermediates, intermediates, and active pharmaceutical ingredients (APIs). Our cutting-edge facility, which is situated in Raichur, Karnataka, is built to the highest industry standards and complies with WHO-GMP, cGMP, EMEA, and USFDA regulations.